Originally posted by Rondec The articles on the two vaccines were published in the New England Journal of Medicine. This is the one on the Pfizer vaccine:
https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 This is on the Moderna:
https://www.nejm.org/doi/full/10.1056/NEJMoa2035389
I think Mark did a good job of explaining it. They recruited volunteers in communities in high levels of COVID, gave have of them placebo shots and half vaccinations and then waited till a certain number of people in the study had developed COVID-19. At that point they broke down what percent were in the vaccinated group and what percent were in the placebo group. Because of the high levels of COVID in our communities, it didn't take to long to get to those points.
---------- Post added 01-18-21 at 05:38 AM ----------
I think that protocol is what they are using. I think there is some concern about the data on AZ's vaccine. So, they had a plan to give all of the volunteers two full doses. It turned out that if you got two full doses of the vaccine, it was 60-ish percent effective.
By accident, they gave 1300 people a half dose followed by a full dose and in that small segment, the vaccine seemed to be 90 percent effective. Now, those were all younger people (under 55) and a relatively small portion of the study and so I do think it is an open question as to how much more effective that protocol is than the other.
How the Oxford/AstraZeneca vaccine went from pole position to troubled start Yes, a half dose followed by a full seems to be the best bet for the AZ vaccine but I don't think they know why yet, it will be interesting to see. Still, if there are no negative effects from doing that way then there's no reason not to proceed, even if the reason is not known. I would like to know how they establish what amount constitutes "one dose".
The AZ vaccine is unlike the Pfizer and Moderna ones as it inserts the genes coding for the spike protein in a harmless virus, so it includes all the other genes that said virus. I have read some reports that suggest the possibility of SARS-CoV-2 and other coronaviruses, such as those that cause the common cold, possess genes which weaken the immune response, so it is essentially defending itself against the host's immune response. It has been theorised that this is the reason why we can catch a cold repeatedly: the immune response is not lasting. Unlike the flu, which re-infects by continually mutating, coronaviruses do not do this, they have developed this alternative strategy. The impact this could have on vaccines, and time will tell if it's the case, is that protection provided by the AZ vaccine may be much more short-live than that from the mRNA vaccines, which contain only the genes coding for the spike protein and none of the others.
It will be very interesting to see.
For now, at least in Europe, it's not possible to choose which vaccine you are given, and that makes sense at this stage with the virus running rampant and vaccines in short suppy. However, if I were given a choice I would certainly pick one of the mRNA vaccines over the AZ one.